<i>FGFR</i> Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC)

<i>FGFR</i> Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC)

Background. <i>FGFR1/2/3</i> fusions have been reported infrequently in aNSCLC, including as a rare, acquired resistance mechanism following treatment with EGFR TKIs. Data regarding their prevalence and therapeutic implications are limited. Methods. The Guardant Health (GH) electronic da...

Full description

Bibliographic Details
Main Authors: Ari Raphael, Elizabeth Dudnik, Dov Hershkovitz, Suyog Jain, Steve Olsen, Lior Soussan-Gutman, Taly Ben-Shitrit, Addie Dvir, Hovav Nechushtan, Nir Peled, Amir Onn, Abed Agbarya, on behalf of the Israel Lung Cancer Group
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Journal of Clinical Medicine
Subjects:
<i>FGFR</i>
<i>FGFR</i> fusion
acquired resistance to EGFR TKIs
lung cancer
liquid biopsy
ctDNA
Online Access:https://www.mdpi.com/2077-0383/11/9/2475

Internet

https://www.mdpi.com/2077-0383/11/9/2475

Similar Items